Novartis Announces Top Line Results for Phase 3 Trial of New Acute Heart Failure Drug

Novartis has announced preliminary results from the RELAX-AHF trial, a phase 3 study of a novel drug, RLX030 (serelaxin), for patients hospitalized wi...

To continue reading, please log in to the right or request an invitation.